Eli Lilly and Company $LLY Shares Purchased by Koshinski Asset Management Inc.

Key Points

• Koshinski Asset Management Inc. increased its stake in Eli Lilly by 9.1% during Q2, now owning 4,673 shares worth $3.64 million.
• Shares of Eli Lilly are currently trading at $803.53, down 1.9%, with a market cap of $760.51 billion and a P/E ratio of 52.52.
• Insider transactions show CEO David A. Ricks and Director J Erik Fyrwald each purchased shares recently, indicating continued confidence in the company's performance.

Koshinski Asset Management Inc. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,673 shares of the company's stock after purchasing an additional 391 shares during the quarter. Koshinski Asset Management Inc.'s holdings in Eli Lilly and Company were worth $3,643,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC grew its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC lifted its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.9%

Shares of NYSE LLY opened at $803.53 on Friday. The company has a market cap of $760.51 billion, a price-to-earnings ratio of 52.52, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock's 50 day simple moving average is $753.09 and its 200 day simple moving average is $766.23.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Erste Group Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Tuesday. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $939.12.

Insiders Place Their Bets

In related news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.